Objective. To determine the rate of infection and all-cause mortality across tofacitinib phase II, phase III, and long-term extension (LTE) studies in patients with moderately to severely active rheumatoid arthritis (RA).Methods. Conclusion. The overall risk of infection (including serious infection) and mortality rates in RA patients treated with tofacitinib appear to be similar to those observed in RA patients treated with biologic agents. The rates of serious infection were stable over time. 550) is an oral JAK inhibitor used for the treatment of rheumatoid arthritis (RA) and has a novel mechanism of action. The JAK family of tyrosine kinases includes JAK-1, JAK-2, JAK-3, and Tyk-2. Tofacitinib preferentially inhibits signaling by heterodimeric receptors associated with JAK-3 and/or JAK-1, with functional selectivity over receptors that signal in pairs of JAK-2 (1). Common ␥-chaincontaining receptors using JAK-1 and JAK-3 include

No abstract

No abstract

No abstract

No abstract